Member Info for Sangijuelas1

And a 20k buyer. Shorts might have got a bit too greedy. Expect back to high 80s soon. Massively oversold

Another fairly recent article on Tregs

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142310/

A more potent strain of what?

So patients expressing high levels of Tregs in their tumours are likely responders to the 0518/Keytruda combo.

The non responders showed low levels of Tregs so with them there is likely another reason for their resistance to immune checkpoint inhibitors.

So when going for Breakthrough Therapy status with the FDA they can point to high probability of success in Treg high subset of patients when they provide a wider sample of patient data.

And if they can continue to show the treatment works in the Treg group then wow

You will not make any money in a biotech from watching the SP.

Follow the science. That's what MSD and Merck/Pfizer are doing

Relevance of tumour biomarkers.
Confirming the role of Tregs in dampening the effect of cancer killer cells and thereby preventing Immune Checkpoint Inhibitors from working where Tregs are over expressed.

This is an emerging area of research and possible solutions to deplete the Tregs are chemotherapy (currently only pre-clinical studies) and some monoclonal antibodies although initial results seem inconclusive.

4D are well ahead with 0518 in terms of clinical progress and safety issues.

Recommend this article for an overview of Tregs and their role in stopping ICIs working and possible therapeutic options.

https://www.frontiersin.org/articles/10.3389/fonc.2021.684098/full

Hi Robins, I am not expecting an RNS tomorrow. We have data coming from 2 different sources. Part A (completed) and Part B (ongoing, open label).

It may be that some Part B data is provided at ESMO but doesn't sound like it from what Rog is saying e. g. info on website rather than RNS.

Part B Clinical Update would need to be an RNS as good or bad news would be highly material and couldn't just be mentioned off the cuff at ESMO.

They said they would provide an update on Part B in late summer or early Autumn.

The RNS today presented additional results following further analysis from trial phases whose main results were already presented at SITC last year. The additional results seem meaningful in that tumour biomarkers have been identified that will indicate which patients are more likely to respond to 0518 with Keytruda.

We are still awaiting for an oncology update on the Phase B part of the trial. We were told that would be in late summer, early autumn.

Oliveira is the one who sends the notification of reduction in holding and he has been late doing it before.

It's hard to say how much Oliveira wants or needs to sell. Needless to say Forte is down heavily again.

I make it.

I realise it was an overreaction to the nuance of what you said so apologies.

I had been reading some of the moaning about the BOD on the other board

I think we are running the risk of imagining that all US investors think and act the same way. For example, Tesla was Marmite for them in that some loved it and others hated it.

I am sure they are much more heterogeneous than that. It's also extremely hard to get their attention. There were 800 or so companies presenting at the Wainwright conference and there are 850 biotech companies on Nasdaq.

Attention will not come overnight. And companies take time to do their due diligence. Sequoia Fund took 12 months before deciding to take a position in Avacta and they did that in a placing. They don't like buying on the open market like the common folk.

Ok but they must be doing something right. They have already got specialist pharma investors on board in Chardan and Oxford Finance along with the more generalist Ladenberg Thalmann.

In addition, we have already participated in sessions with Cantor Fitzgerald and H C Wainwright with Oppenheimer coming up next week.

I think there is a convergence here of Oliveira selling, which in itself is a hangover from the Woodford debacle and the shorts looking to push it down further. There's not really a lot the company can do to resolve that. However, the seller will run out of shares and the quant fund must have a target bottom.

You can see that they are looking to tell a story more to get US investors on board, hence the presentations are now all starting with how Dunc and Al were troubled by the safety profile problems of traditional drugs and how they came across LBPs.

A lot of the work raising the profile with US investors would have been dealt with by John Beck who sadly passed very recently. I expect it was him who put in place the Oxford Finance deal.

I agree about the open shirt look myself as I am very much attached to suits. However he waa working from home in some of those interviews where loungewear is often recommended.

Have you got any idea how hard him and Alex are working to get this right?
And you are upset he doesn't put on a clown show for investors.

Newsflash - we need US institutional investors on board. They aren't looking for a charismatic clown show. They are looking at data from trials.

4D achieved what they did in oncology in a very small group of patients. The market wants to see that replicated in a larger group of patients.

DP and AS have built the company up to where it is today from nothing.

What the actual **** have you done to be able to criticise them?

Probably shorts taking profit from sells in the 80s or higher

I have lost discipline and gone into my cash buffer and bought more. This because I didn't want to sell Angle (waiting news) or Avacta (too low).

There are. Chunky and their brokers probably know about the seller.
Normally they would hold off but they aren't.